Novartis gets European OK for biosimilar of Amgen's Enbrel
June 27, 2017 at 01:31 AM EDT
ZURICH, June 27 (Reuters) - Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.
